The agreement will enable NaviFUS and Brainlab to explore the benefits of combining focused ultrasound and surgical guidance technologies.
NaviFUS (TaiEx: 6872) recently signed an earlystage cooperation agreement with Brainlab, a global leader in surgical imaging and navigation. The agreement will enable the companies to combine focused ultrasound (FUS) and surgical guidance technologies and identify methods that could accelerate the clinical integration of these approaches.
Dr. Yu Hsiang-Yu, Director of the Epilepsy Department at Taipei Veterans General Hospital Neurological Center, held a press conference earlier today summarizing the results of the previous pilot clinical trial using focused ultrasound (FUS) to treat patients with epilepsy and promoting the follow-up study that is currently underway.
NaviFUS Corporation (6872), an innovator of focused ultrasound technology announced that its NAVIRFA® Scope product has consecutively received approvals for the Sales License for Class II Medical Device from TFDA (Taiwan Food and Drug Administration) and the 510(K) Premarket Notification from US FDA in early May.
The “NaviFUS Focused Ultrasound System” developed by NaviFUS Corporation recently won Gold at the 2022 Edison Awards – Science & Medical Outpatient Treatment category on Apr. 22, 2022. Also competing in this category were other innovative products by renowned companies Abbott Laboratories and Spark Biomedical.
NaviFUS Corporation’s “Neuronavigation-guided Focused Ultrasound System” has recently been shortlisted for the 2022 Edison Award – Science & Medical Outpatient Treatment category – together with global pharmaceutical giant Abbott and Spark Medical Inc. (market value: US$4.4 billion). Final results for the gold, silver, and bronze medals will be announced in April in Florida, USA. The news is an affirmation that NaviFUS can compete side by side with other first-rate companies around the world, and Taiwan’s innovative talent is once again visible on the world stage.
We’re not keeping it a secret anymore. We are proud to announce NaviFUS® Model 101 has been chosen for the 2022 Edison Awards Finalists in Outpatient Treatment
The Finalists of the 2022 Edison Best New Product Awards® were chosen as the “best of the best” by 3000 of the world’s top senior business executives, academics, and innovation professionals.
We are excited to announce that NaviFUS® Model 101 Neuronavigation-guided focused ultrasound system is nominated for the 2022 Edison Awards! Congratulations to our team members for the incredible work they do! The Edison Awards™, named after Thomas Alva Edison, is a leader in globally recognizing, honouring and fostering innovation and innovators to create a positive impact in the world.
Pilot Study of Focused Ultrasound for Drug-Resistant Epilepsy
Researchers in Taiwan recently published the data from a small pilot clinical trial testing the safety and efficacy of using focused ultrasound to provide neuromodulation for patients with drug-resistant epilepsy.
Participants received low-intensity focused ultrasound in the seizure origination zone from the NaviFUS neuronavigation-guided system.
Results from a study published in Epilepsia suggest that focused ultrasound, which can be used to non-invasively target circuits in the brain, may benefit some patients with epilepsy who experience seizures that do not respond to standard anti-seizure medications.
